Member Info for mazik

FigTreeHarry,
We cannot help with Newbies around as they wet their pants on slight weakness in contrast holding and adding, relaxed while Nigel is discussing with potential partners... IMO...awaiting update for Xmas party..GLA

If we have partnership or collaboration with AZ or Biontech, regarding vaccine delivery that will be a new era for N4P...£1 plus

Grab before its all blue..IMO

MM selling on premium of quoted price, interesting :-)

Definately high return with N4p, MM games giving opportunity for topping up 60k , partnership talk RNS will take us straight to multiples of today's price..IMO

Topup displayed as sales, not that it matters...GLA

to look at an oral system then you are going to have to have a different delivery system, that’s going to be essential so that, again, is where Nuvec works.

N4P has already seen with other work, how good Nuvec is at staying in the upper intestine and now we’ve shown that it not only protects DNA from nucleic but also it protects it in the acidic environment., That gives us confidence that we can press on with our investigations for showing how Nuvec can be used as an oral system and I really believe that having an oral delivery for a DNA or RNA vaccine could be a game changer in this this space.

MM have hoovered some from weak holders...

Towards 20p by afternoon :-) Game changer on Next RNS

Topped up :-)

Dan,
Could u let me know what help will be to us with collaboration with nanometrics? Am i missing a plot?

Hah! Hah! Omg , 100 million will do fine. At least I can pay off my remaining mortgage

FigTreeHarry,
Happy to take a backseat for now, though I will be happy to top up tomorrow if it stays at this level, though Nigel has already mentioned about partnership if it is announced tomorrow then many would feel left out...under 20 still a bargain imo....gla

Montyboz agree with you, at present it will be logistic nightmare, for global requirement feel the only sustainable solution is Oral delivery system.. IMO

Here is some extracts from the Directors Q/A I find interesting, its complicated as many might prefer an Oral form of delivery system with Nuvec too, find Nigel's answer convincing what we are looking forward and what we have in front of us.No wonder he has mentioned regarding partnership and collaboration in recent RNS.
"We’ve already seen with other work, how good Nuvec is at staying in the upper intestine and now we’ve shown that it not only protects DNA from nucleic but also it protects it in the acidic environment., That gives us confidence that we can press on with our investigations for showing how Nuvec can be used as an oral system and I really believe that having an oral delivery for a DNA or RNA vaccine could be a game changer in this this space.
RNS, we’re starting our COVID proof of concept in vivo work imminently and that’s for our un-optimised version of the Nuvec system so once we have this data, we shouldn’t take too long, we will then look to do another follow on in vivo study with optimised versions of the product. So, we’re running the optimisation work in parallel to that first study so that we can then pull all the learning together to come up with a further proof of concept work because the continued updates of the work as we go, enables us to keep reaching out to people to say, this is how Nuvec works."

The difference between what we call vaccine efficacy and vaccine efficiency. So, a vaccine efficacy is ‘does a vaccine work’, and that’s going to be determined by whoever owns the active part of the vaccine, be at Pfizer, Medina. The FDA has already said that they’re going to drop the hurdle rate for vaccine efficacy to just 50% so that means efficiency of the vaccine is going to be vital and what efficiency means is, so you got an effective vaccine, but how many people can the vaccine actually be delivered to and that’s where Nuvec comes in.

Partnership magic word from Nigel himself, a RNS if in talks, straight £100 million market cap..IMO

Formulated vaccine product, it’s got to be stable over time so showing that Nuvec can be dried, stored, and reconstituted is part of that data that we’re going to need to talk to partners. So, showing this is a really good step forward with this work, but it’s not just about being stable, it’s about how it’s stable.
What’s key for Nuvec is our early data looks like we’ll be able to store it, just at room temperature so storing at room temperature would be fine. That’s a major difference compared to lipid systems, for example, where people are using it for mRNA, that require freezing so the Pfizer product, one of the vaccines for COVID for Pfizer and BioEnTech, that has to be stored at minus 92 degrees. So that’s going to be a major issue when it comes to rolling out that vaccine when it’s proven to be successful.
For us, the next steps will be to demonstrate how long our formulated Nuvec products can be stored in room conditions etc. and then still work.
So, doing that formulation stability work is crucial to helping partnership discussions.
https://www.***************************/n4-pharma-qa-confirming-nuvecs-versatility-lonn4p/

Mr.Cruiser,
Agree with you,once in a life time opportunity... effective vaccine delivery system is a must, here we are talking million or billion of doses needed all over the globe..Astra Zenica are rolling out in March highly likely that Nuvec could be proven as the delivery system which has been worked for the last 4 years. Head start and it will be bingo...for holders. IMO

Savvyinvestor very balanced opinion, I concur if successful this could be a game changer.